Page 37 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Prospective DPYD genotyping: ready for prime time
26 February 2015.
34. Falvella FS, Caporale M, Cheli S, et al. Undetected Toxicity Risk in Pharmacogenetic Testing for
Dihydropyrimidine Dehydrogenase. Int J Mol Sci. 2015;16(4):8884-8895. 2
35. Deenen MJ, Cats A, Sechterberger MK, et al. Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. J Clin Oncol. 2011;Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2011.
(suppl: abstract 3606).
36. Sistonen J, Smith C, Fu YK, Largiader CR. A new DPYD genotyping assay for improving the safety
of 5-fluorouracil therapy. Clin Chim Acta. 2012;414:109-111.
37. Swen JJ, Nijenhuis M, De BA, et al. Pharmacogenetics: from bench to byte--an update of
guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
38. Henricks LM, Lunenburg CATC, Meulendijks D, et al. Translating DPYD genotype into DPD
phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16(11):1277-1286.
39. Pirmohamed M. Acceptance of biomarker-based tests for application in clinical practice: criteria
and obstacles. Clin Pharmacol Ther. 2010;88(6):862-866.
40. Gillis NK, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic
testing: the debate continues. Clin Pharmacol Ther. 2014;96(6):655-657.
41. Di Francia R, Berretta M, Catapano O, Canzoniero LMT, Formisano L. Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications.
Clin Chem Lab Med. 2011;49(7):1105-1111.
42. Swen JJ, Wilting I, de Goede AL, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol
Ther. 2008;83(5):781-787.
43. Swen JJ, Guchelaar HJ. Just how feasible is pharmacogenetic testing in the primary healthcare
setting? Pharmacogenomics. 2012;13(5):507-509.
44. Dunnenberger HM, KR C, JM H, et al. Preemptive Clinical Pharmacogenetics Implementation:
Current Programs in Five US Medical Centers. Annu Rev Pharmacol Toxicol. 2015;55:89-106.
45. Ratain MJ, Johnson JA. Meaningful use of pharmacogenetics. Clin Pharmacol Ther. 2014;96(6):650-
652.
46. Boisdron-Celle M, Capitain O, Metges J-P, et al. Prevention of 5-FU-induced health-threatening
toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach. J Clin Oncol. 2013;Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2013.
47. Traore S, Michele B-C, Hunault G, et al. DPD deficiency: Medicoeconomic evaluation of pretreatment screening of 5-FU toxicity. J Clin Oncol. 2012;Conference: Gastrointestinal Cancers Symposium San Francisco:01 Feb 2012.
48. Boisdron-Celle M, Biason P, Gamelin E, Morel A. Dihydropyrimidine dehydrogenase and fluoropyrimidines: A review of current dose adaptation practices and the impact on the future of personalized medicine using 5-fluorouracil. Colorectal Cancer. 2013;2(6):549-558.
49. FDA. U.S. Food and Drug Administration. Approved drugs: Cetuximab in Combination with Folfiri / Therascreen. 2012; http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm310933.htm. Accessed 25 May 2015.
50. Van CE, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417.
35